Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4,163.2% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 67.6% | 77.4% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $3 | $13 | $6 | $2 |
| SG&A Expenses | $4 | $16 | $6 | $2 |
| Sales & Mktg Exp. | $1 | $3 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $16 | $6 | $2 |
| Operating Income | -$4 | -$17 | -$6 | -$2 |
| % Margin | -1,108.7% | -207,542.2% | – | – |
| Other Income/Exp. Net | $1 | -$62 | -$1 | -$0 |
| Pre-Tax Income | -$3 | -$78 | -$8 | -$2 |
| Tax Expense | $0 | $3 | -$0 | -$0 |
| Net Income | -$3 | -$78 | -$8 | -$2 |
| % Margin | -852.4% | -931,940.1% | – | – |
| EPS | -0.007 | -0.24 | -0.051 | -0.025 |
| % Growth | 97.3% | -367.8% | -108.5% | – |
| EPS Diluted | -0.007 | -0.24 | -0.051 | -0.025 |
| Weighted Avg Shares Out | 470 | 323 | 149 | 95 |
| Weighted Avg Shares Out Dil | 470 | 323 | 149 | 95 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $4 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$17 | -$5 | -$2 |
| % Margin | -813.3% | -207,095.9% | – | – |